checkAd

     189  0 Kommentare Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting 2023 - Seite 3

    The Company is on track for sharing the MARCH Part B 48-week EOT data in the fourth quarter of 2024.

    Late-Breaker Oral Presentation – Phase 2 SOLSTICE

    The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Date: Monday, November 13 at 3:00 p.m. ET
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France

    Late-Breaker Poster Presentation – Phase 2 MARCH Part B

    VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Date: Monday, November 13 at 1:00 p.m. ET
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital

    The abstracts for these and the other six AASLD presentations are available under Events & Presentations in the Investors section of the Vir website here. The final presentations will be posted after 3:30 pm ET today.

    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th. A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

    Lesen Sie auch

    About Chronic Hepatitis B

    Chronic hepatitis B (CHB) infection remains an urgent global public health challenge associated with significant morbidity and mortality. Approximately 300 million people around the world are living with CHB, and approximately 900,000 of them die from associated complications each year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily therapy and/or poor tolerability. Vir is working to achieve a functional cure for the millions of people with CHB around the world through its broad and differentiated portfolio.

    Seite 3 von 6



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting 2023 - Seite 3 Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential clinical impact that VIR-3434, an investigational monoclonal antibody (mAb), and …

    Schreibe Deinen Kommentar

    Disclaimer